FARMINGDALE, N.Y., Oct. 16, 2013 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, exhibited at the 28th Annual Meeting of the North American Spine Society (NASS) in New Orleans, Louisiana on October 9-11, 2013.
The North American Spine Society is a multidisciplinary medical organization dedicated to fostering the highest quality, evidence-based and ethical spine care by promoting education, research and advocacy. Its annual meeting held last week is one of the largest multidisciplinary continuing medical education (CME) meetings for spine specialists in North America. The objective of this meeting was to present current research and data, promote discussion of new scientific and technological developments and foster research and training in the field of spinal disorders. The meeting was attended by more than 3,000 medical professionals, the vast majority being from the United States and approximately 30% from around the globe. More than 73% of attendees declared that they influence purchasing decisions.
Misonix's BoneScalpel, a unique ultrasonic osteotome for tissue-selective bone dissection, was demonstrated at this year's NASS Annual Meeting. BoneScalpel enables en-bloc bone removal and refined osteotomies while sparing elastic soft tissue structures such as important nerves and arteries. Therapeutic ultrasound is well-known for its coagulative effects and the BoneScalpel has been reported to substantially reduce blood loss in multilevel spinal osteotomies.
The Misonix BoneScalpel is increasingly being adopted by more surgeons throughout the country. Dr. Paul Holman, a leading orthopedic surgeon at Houston Methodist Hospital said, "I view the BoneScalpel as one of the three most important technologies to enter the spine world in the last 10 years. It has been of tremendous value to my practice particularly in adult deformity surgery where multiple laminectomies and Smith-Peterson osteotomies are needed. The precision and coagulative effect of the bone scalpel also facilitate more complex procedures such as Pedicle Subtraction Osteotomies, which are typically associated with significant blood loss. Use of the BoneScalpel allows for efficient bone removal and helps to retain the local bone for spinal fusion."
His colleague, Dr. Isador Lieberman from Texas Back Institute in Plano, Texas added, "What once required one hour of meticulous decompression of compromised spinal nerves with mechanical tools can now be accomplished in less than 15 minutes and I am now routinely scheduling shorter operative times for my multi-level decompressions."
Michael A. McManus, Jr., President and Chief Executive Officer of Misonix comments, "We had an excellent NASS meeting with approximately 200 attendees visiting our exhibit seeking a product demonstration. The knowledge about BoneScalpel is clearly increasing, peer-to-peer referrals are creating a great deal of excitement and surgeons are increasingly requesting trials in the operating room."
Mr. McManus added, "We are extremely pleased by the expanding utilization of the BoneScalpel in advanced spinal surgeries for removal of pain causing nerve compressions and for performing complex osteotomies in spinal fusions and deformity surgeries. It is remarkable that numerous leading surgeons at the country's most important spine centers now consider the BoneScalpel as one of the most significant technological advances in spine surgery within the last decade. We are proud to have participated at this leading industry conference and gratified with the growing reputation of the BoneScalpel."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.